Adiponil: Effective Weight Management Solution | Incepta Pharmaceuticals
Adiponil 120 400.00৳ Strip
Back to products
Brimodin Plus Eye Drops | Effective Glaucoma & Ocular Hypertension Treatment
Brimodin Plus 0.2% + 0.5% 110.00৳ Ophthalmic Solution (5ml)

Brimodin 0.2%

80.00৳ Ophthalmic Solution (5ml)

  • Brimodin is a preservative-free ophthalmic solution available in 0.2%, 0.15%, and 0.025% concentrations, designed to manage intraocular pressure in glaucoma and ocular hypertension patients.
  • It utilizes an innovative Ophthalmic Squeeze Dispenser (OSD) for ease of use.
  • Brimonidine, the active ingredient, reduces aqueous humor production and enhances uveoscleral outflow for effective eye pressure management.
  • This solution provides rapid action with effects lasting up to 12 hours.
  • Always follow healthcare provider recommendations for safe usage.
Brand

Incepta Pharmaceuticals Ltd

Generics

Brimonidine Tartrate

Type

Ophthalmic Solution

0 People watching this product now!
Description

Indications

Brimodin 0.2% ophthalmic solution is specifically designed to reduce intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension.

Brimodin 0.15% ophthalmic solution effectively manages intraocular pressure in individuals with chronic open-angle glaucoma or ocular hypertension.

Brimodin 0.025% ophthalmic solution alleviates eye redness resulting from minor irritations.

Description

Opsonin Pharma proudly introduces Bangladesh’s first preservative-free sterile eye drops, utilizing the innovative Ophthalmic Squeeze Dispenser (OSD) technology.

Brimodin is an alpha-adrenergic receptor agonist that exhibits a peak hypotensive effect approximately two hours post-administration. Research indicates that Brimodin operates through a dual mechanism: it reduces aqueous humor production and enhances uveoscleral outflow.

Pharmacology

Brimonidine is a selective α-2 adrenergic receptor agonist, primarily acting on α-2 receptors. Topical application of Brimonidine Tartrate eye drops effectively decreases intraocular pressure (IOP) in patients. When administered as directed, Brimonidine Tartrate lowers elevated IOP while having minimal impact on cardiovascular parameters. The onset of action is rapid, with peak efficacy observed two hours after dosing, and the effects can last 12 hours or more. Studies suggest that Brimonidine Tartrate reduces IOP by decreasing aqueous humor production and increasing uveoscleral outflow.

Dosage & Administration

  • 0.2% Ophthalmic Solution: Instill one drop in the affected eye(s) three times a day, spaced approximately 8 hours apart. This solution may be used alongside other topical ophthalmic medications for intraocular pressure reduction. If using multiple products, administer them at least 5 minutes apart.
  • 0.15% Ophthalmic Solution: Administer one drop in the affected eye(s) three times daily, approximately 8 hours apart.
  • 0.025% Ophthalmic Solution: Use one drop in the affected eye(s) every 6-8 hours, not exceeding four times daily. Ensure a minimum 5-minute interval between different topical ophthalmic products.

Always follow your healthcare provider’s instructions regarding medication use.

Interactions

While specific studies on drug interactions with Brimodin ophthalmic solution are limited, caution is advised when used concurrently with central nervous system depressants (such as alcohol, barbiturates, opiates, sedatives, or anesthetics). Alpha-agonists can potentially lower heart rate and blood pressure, so care should be taken when using with beta-blockers (both ophthalmic and systemic), antihypertensives, or cardiac glycosides. Tricyclic antidepressants may diminish the hypotensive effect of systemic clonidine, and it’s unclear how they interact with Brimodin. Therefore, caution is warranted for patients on these medications.

Contraindications

Brimonidine Tartrate ophthalmic solution is contraindicated in individuals with known hypersensitivity to Brimonidine Tartrate and those undergoing monoamine oxidase (MAO) inhibitor therapy.

Side Effects

Common side effects (occurring in approximately 10-30% of users) include dry mouth, ocular hyperemia, burning or stinging sensations, headache, blurred vision, foreign body sensation, fatigue, conjunctival follicles, allergic reactions, and eye itching. Less common effects (3-9%) may involve corneal staining, photophobia, eyelid redness, ocular pain, dry eyes, tearing, respiratory symptoms, eyelid swelling, dizziness, and more. Rare effects (less than 3%) can include lid crusting, conjunctival hemorrhage, unusual taste, insomnia, and others.

Pregnancy & Lactation

Currently, there are no well-controlled studies in pregnant women. In animal studies, Brimonidine has been shown to cross the placenta, entering fetal circulation to some extent. Therefore, Brimonidine Tartrate ophthalmic solution 0.2% should be administered during pregnancy only when the benefits to the mother outweigh potential risks to the fetus. It’s unclear if this medication is excreted in human milk; however, animal studies indicate it is. Decisions regarding breastfeeding should consider the importance of the drug to the mother.

Precautions & Warnings

Despite showing minimal effects on blood pressure in clinical studies, caution is recommended for patients with severe cardiovascular conditions. Brimodin should also be used carefully in individuals with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

Therapeutic Class

This product belongs to the class of medications used for miotics and glaucoma management.

Storage Conditions

Store below 30°C in a cool, dry place away from light. Keep out of reach of children. Avoid touching the dropper tip to surfaces to prevent contamination. Discard any remaining solution 30 days after first opening.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Brimodin 0.2%”

Your email address will not be published. Required fields are marked *

About brand
Shipping & Delivery